A 19th-century dye still used to treat methemoglobinemia, now trending in biohacker circles for its effects on mitochondria. But the Alzheimer's trials failed, there are no human longevity studies, and the serotonin syndrome risk with common antidepressants is a real safety concern.
Methylene blue (methylthioninium chloride) is a phenothiazine dye whose redox chemistry lets it cycle easily between oxidized and reduced forms, so it can shuttle electrons in biological systems, a bit like a tiny rechargeable battery inside your cells.1
At low doses it works as an electron cycler in the mitochondrial respiratory chain, with antioxidant and respiration-enhancing effects; at higher doses the effects reverse, a classic hormetic dose response.1
In human fibroblasts, methylene blue increased mitochondrial complex IV by 30 percent and raised oxygen consumption.2 Because mitochondrial dysfunction is one of the hallmarks of aging, the mechanism maps neatly onto longevity biology at the cellular level.
This is why researchers are paying attention. It's also why the biohacker community has run far ahead of the evidence — because the mechanism is so cleanly aligned with aging theory that it's easy to extrapolate from cell studies to human longevity. That extrapolation is the problem.
In cell culture, low-dose methylene blue extended the replicative lifespan of human fibroblasts by more than 20 population doublings.2 In skin fibroblasts from healthy donors and from people with progeria, it stimulated proliferation and delayed senescence more effectively than other antioxidants tested, and it passed an irritation test on a reconstructed skin model.3 These are cell studies, not evidence of visible skin rejuvenation in people.
In animal models, low doses have been used for memory enhancement and for neuroprotection against mitochondrial dysfunction.1 None of this has been shown to translate into longer or healthier lives in people.
The most extensive human testing came through TauRx Therapeutics' tau-aggregation inhibitors, stabilized forms of methylene blue (LMTM, later called HMTM), tested in three phase 3 trials in Alzheimer's disease and mild cognitive impairment.
In the first trial, neither high dose showed any benefit on the co-primary cognitive and functional outcomes.4 In the second (800 patients), the analysis plan was revised before unblinding to compare non-randomized monotherapy subgroups, and only those re-analyses were positive.5 In the third (598 people), the drug could not be shown to differ from control on the co-primary endpoints at 52 weeks, which the authors attribute to activity of the low-dose control.6 Positive results from re-analyses and subgroups of trials that missed their randomized endpoints are the weakest kind of signal.
The trials share a blinding problem: methylene blue turns urine blue-green, so each "control" group took a low dose of the drug to mimic the color change.4–6 That means none had a truly untreated comparison group.
There are zero published randomized controlled trials examining whether methylene blue microdosing slows biological aging, improves long-term cognitive trajectories, or extends healthspan in healthy adults. The consumer longevity use case is built almost entirely on mechanistic extrapolation from cell and animal studies — a category of evidence that has a poor track record of translating to human benefit.
Methylene blue has a genuinely interesting mitochondrial mechanism and encouraging cell and animal data. But human evidence for longevity is absent, and the most rigorous human testing (the Alzheimer's trials) missed its randomized endpoints. Combined with real safety concerns, the evidence does not support its use as a longevity intervention in healthy adults.
Methylene blue has been used safely in clinical medicine for over a century — but at specific doses, for specific indications, under medical supervision. The biohacker use case (chronic low-dose self-administration for longevity) has a different risk profile that deserves serious attention.
Methylene blue inhibits monoamine oxidase A (MAO-A), which confirms why it can precipitate serotonin toxicity in people taking SSRIs.7 In a review of reported central nervous system reactions to methylene blue, 13 of 14 cases were serotonin toxicity, mostly after intravenous doses given during surgery to people on serotonergic antidepressants.8 Combining it with SSRIs, SNRIs, triptans or St. John's wort can cause agitation, confusion, fever, muscle rigidity and, in severe cases, seizures and death.
Most reported cases followed intravenous use in hospitals, but oral use with serotonergic drugs carries the same mechanism. Antidepressants are among the most widely prescribed medicines, so this is not a niche concern.
People with glucose-6-phosphate dehydrogenase (G6PD) deficiency, an inherited enzyme condition, should not take methylene blue without specialist advice: it is on the list of drugs that can trigger hemolysis (destruction of red blood cells) in G6PD deficiency.9
Methylene blue has a hormetic, inverted-U dose response: low doses act as an electron cycler and antioxidant, while higher doses have the opposite effects.1 The window for chronic use at "longevity" doses has not been defined in people, and more is not better.
Laboratory and aquarium grades of methylene blue are not made for human consumption and are not held to the impurity limits of pharmaceutical (USP) grade. If you use it at all, use pharmaceutical-grade product under medical supervision.
Critical safety note: If you take any SSRI, SNRI, triptan, or other serotonergic medication, do not use methylene blue without explicit guidance from your prescribing physician. The serotonin syndrome risk is pharmacologically established and potentially lethal. This is not a theoretical concern.
Methylene blue is one of the most mechanistically interesting compounds in longevity biology, and its long clinical use for methemoglobinemia, dating back to the dye's early medical uses in the 19th century, gives it a foundation that novel compounds lack.10
But the honest assessment in 2026 is that the gap between preclinical promise and human longevity evidence is wider for methylene blue than for most compounds getting comparable hype. The Alzheimer's trials — the most rigorous human testing of its neuroprotective potential — produced negative results. There are no human longevity trials. The consumer use case is built on mechanism extrapolation, not outcome data. And the safety concerns (serotonin syndrome, G6PD, dose-response, purity) are more serious than the typical longevity supplement.
Watch this space. Methylene blue may yet prove to be a genuine longevity tool — its mechanism is too well-aligned with aging biology to dismiss entirely. But right now, it belongs in the "fascinating but unproven" category, not in your daily protocol. If you do choose to experiment, do so under medical supervision, with pharmaceutical-grade product, at established low doses, and only after confirming you have no contraindications.